Reata Pharmaceuticals (RETA) Reports Q2 Loss of $0.05/Share

Reata Pharmaceuticals (NASDAQ: RETA) reported Q2 EPS of ($0.05), versus ($0.11) reported last year. Revenue for the quarter came in at $12.4 million, versus $12.4 million reported last year.

For earnings history and earnings-related data on Reata Pharmaceuticals (RETA) click here.

You May Also Be Interested In

• Burry doubles down on Nebius short after stock surges 34% on earnings
• Pulmatrix (PULM) Reports Q2 Loss of $0.29
• Ondas Holdings Inc. (ONDS) Misses Q2 EPS by 9c